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Abstract
Multiple neurodegenerative diseases are characterized by aggregation of tau molecules. Adult humans express six
isoforms of tau that contain either 3 or 4 microtubule binding repeats (3R or 4R tau). Different diseases involve
preferential aggregation of 3R (e.g Pick disease), 4R (e.g. progressive supranuclear palsy), or both 3R and 4R tau
molecules [e.g. Alzheimer disease and chronic traumatic encephalopathy]. Three ultrasensitive cell-free seed
amplification assays [called tau real-time quaking induced conversion (tau RT-QuIC) assays] have been developed
that preferentially detect 3R, 4R, or 3R/4R tau aggregates in biospecimens. In these reactions, low-fg amounts of a
given self-propagating protein aggregate (the seed) are incubated with a vast excess of recombinant tau
monomers (the substrate) in multi-well plates. Over time, the seeds incorporate the substrate to grow into amyloids
that can then be detected using thioflavin T fluorescence. Here we describe a tau RT-QuIC assay (K12 RT-QuIC) that,
using a C-terminally extended recombinant 3R tau substrate (K12CFh), enables sensitive detection of Pick disease,
Alzheimer disease, and chronic traumatic encephalopathy seeds in brain homogenates. The discrimination of Pick
disease from Alzheimer disease and chronic traumatic encephalopathy cases is then achieved through the
quantitative differences in K12 RT-QuIC assay thioflavin T responses, which correlate with structural properties of the
reaction products. In particular, Fourier transform infrared spectroscopy analysis of the respective K12CFh amyloids
showed distinct β-sheet conformations, suggesting at least partial propagation of the original seed conformations
in vitro. Thus, K12 RT-QuIC provides a single assay for ultrasensitive detection and discrimination of tau aggregates
comprised mainly of 3R, or both 3R and 4R, tau isoforms.
Keywords: RT-QuIC, Tau, Pick disease, Alzheimer disease, Chronic traumatic encephalopathy, Neurodegeneration,
Protein misfolding, Seed, Primary age-related tauopathy
Introduction
Recent calls for better biomarkers of neurodegenerative dis-
eases [20] have elicited efforts to detect disease-associated
protein aggregates in diagnostically-accessible tissues.
Among the novel approaches employed are those exploiting
the self-propagating property of amyloid or pre-amyloid ag-
gregates, that is, the ability to act as seeds that can grow by
incorporating more monomers of their constituent proteins
by seeded polymerization. Seeding activities in biospecimens
from disease cases can be amplified by many orders of mag-
nitude in vitro by using recombinant protein monomers as
substrates and either sonication [1] or shaking [3, 9] to accel-
erate polymerization. The formation of amplified amyloid
products in such reactions can be detected over time in
multi-well plates using the amyloid-sensitive dye thioflavin T
(ThT) [9, 33]. For example, real time quaking-induced con-
version (RT-QuIC) assays have been adapted to the ultrasen-
sitive detection of prions [2, 18, 24–26, 32, 33] as well as
pathologic forms of α-synuclein [4, 8, 13, 19, 30] and tau [21,
23, 28]. These assays are providing a basis for accurate mo-
lecular diagnosis of the associated neurodegenerative diseases
[5, 18, 35].
Diseases involving tau pathology include those with
preferential aggregation of 3 microtubule binding-repeat
(3R), 4-repeat (4R), or both 3R and 4R (3R/4R) tau
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isoforms. Previously, our lab has developed tau RT-QuIC
assays optimized to detect the mainly 3R aggregates of
Pick disease (PiD) [27]; the 3R/4R aggregates of Alzheimer
disease (AD) and chronic traumatic encephalopathy
(CTE) [21]; or the 4R aggregates of progressive supra-
nuclear palsy (PSP), corticobasal degeneration (CBD),
frontotemporal dementias associated with MAPT muta-
tions (FTDP 17 MAPT) and others [29]. In these assays,
tau seeds from crude brain homogenates or cerebrospinal
fluid (CSF) are added to reaction mixtures containing
purified tau fragments truncated at different points in the
microtubule binding domains to help confer seeding se-
lectivity. For instance, the modified 3R tau fragment
K19CFh forms fibrils when seeded with PiD brain hom-
ogenate as dilute as 10− 9, but not with PSP brain hom-
ogenate even at a 105-fold higher concentration [27]. In
contrast, the modified 4R tau fragment K18CFh amplifies
4R tau aggregates [29], and a tau fragment spanning the
cross-β core of AD tau fibrils (τ306–378) selectively amp-
lifies mixed 3R/4R tau seeds [21]. Figure 1 schematically
represents the recombinant tau fragments used in differ-
ent tau RT-QuIC assays.
Recently, structures of tau filaments of AD, CTE, and PiD
have been solved by cryo-electron microscopy [14–16, 36].
These structures reveal that the 3R tau filaments characteris-
tic of PiD differ in conformation from the 3R/4R filaments of
AD and CTE. Since we previously achieved selective amplifi-
cation of 3R PiD seeds with K19CFh, and amplification of
3R/4R AD and CTE seeds with τ306–378, we investigated
whether a hybrid tau fragment could be seeded by PiD, AD,
and CTE tau aggregates. We chose an extended 3R substrate
that included amyloid core residues of both the PiD and AD
tau filaments. This tau fragment, henceforth referred to as
K12CFh (K12 cysteine-free and histidine tagged), spans the
first, third and fourth repeats (R1, R3 and R4, respectively),
extends to residue 400, and is a modification of the previ-
ously described K12 construct [34]. Our new tau assay, K12
RT-QuIC, detects 3R and 3R/4R tau seeds with similar sensi-
tivity while at the same time discriminating PiD seeds from
the others based on conformational differences between the
amplified RT-QuIC products.
Methods
Brain tissue samples and compliance with ethical
standards
Deidentified post-mortem brain samples were obtained
from sources indicated in Table 1 and Acknowledge-
ments in [21]. As samples were obtained from deceased,
de-identified, consenting individuals, no further ethical
approval was required.
Neuropathology
Brains analyzed in this work were prepared as previously
described with the numbering of patients following that
in Table 1 in [21]. Briefly, one half of a patient brain was
formalin fixed and the other half frozen. Diagnoses of
Fig. 1 Comparison of the K12 tau RT-QuIC assay described in this work with the other three currently available tau RT-QuIC assays. Fibril
structures were taken from PDB files originally published in [14–16, 36]. Cysteines in the canonical tau sequences were mutated to serines (*) or
alanine (★) for recombinant tau fragments used in tau RT-QuIC assays. The 3R, AD, and 4R RT-QuIC assays mentioned in this figure have been
described previously [21, 23, 27, 29]
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Table 1 End-point quantification of tau seeding activity in brain tissue across tau RT-QuIC assays
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fixed tissues were made using the stains described in [6,
21]. Tissue samples in this study were collected from
frontal cortex except for CTE and primary age-related
tauopathy (PART) samples which were from temporal
cortex. 10% w/v brain homogenates of frontal cortex tis-
sue were prepared in ice-cold PBS using 1 mm silica
beads (BioSpec, 11079110z) and Beadbeater (BioSpec) or
BeadMill 24 (Fischer). K. N. provided CTE; B. G. pro-
vided all other samples, PiD, AD, diseases with 4R tau
deposits, and controls lacking tau pathology.
Purification of recombinant K12CFh tau
A cloning cassette encoding the K12 tau fragment (resi-
dues 244–275 and 306–400 of the full-length human tau
sequence) with an alanine mutation at residue 322 [17],
thereby rendering it cysteine-free (K12CF), was introduced
between the Ndel and XhoI sites of the pET28 bacterial
vector resulting in a histidine tag at the N-terminal
(K12CFh). The cysteine was mutated in order to prevent
disulfide-mediated dimerization of the K12 molecules.
Purification of K12CFh follows the steps described in [27,
28] and is summarized schematically in Additional file 1.
Briefly, K12CFh was expressed in BL21(DE3) E. coli fol-
lowing the overnight autoinduction protocol described in
[27]. Cells were centrifuged at 3750 rpm for 35min at
4 °C, resuspended in buffer A (10mM Tris, 500mM NaCl,
5 mM imidazole, pH 8.0), and probe sonicated 3 × 45 s at
25% pulse with 15 s pause. Lysates were filtered through
0.45 μM syringe filter prior to nickel affinity chromatog-
raphy using a His-Trap FF (GE Healthcare 17–5255-01)
column. Sequential wash steps with 13 and 21% buffer B
(10mM Tris, 500mM NaCl, 200mM imidazole, pH 8.0)
over 5 and 7 column volumes each eluted two contami-
nants observed previously in K18CFh, K19CFh, and τ306–
378CFh purifications. K12CFh was eluted over a linear
gradient of 46–200mM imidazole over 8 column volumes.
Fractions were pooled and precipitated in 4 x volumes of
ice-cold acetone in 4 °C overnight. Acetone precipitant
was pelleted at 10,000 x g for 20min and washed with a
further 20mL acetone with a repeat centrifugation at 10,
000 x g for 20min. Acetone was decanted and pellets dis-
solved in 8M Guanidine-HCl (GdnHCl) in PBS. The dis-
solved K12CFh was desalted into PBS, pH 7.0 using PD-10
desalting columns (GE Healthcare, 17–0851-01). Removal
of guanidine was verified via UV absorbance readings. The
K12CFh concentration was adjusted to ~ 0.75mg/mL and
aliquots stored at − 70 °C until use.
K12 RT-QuIC
The K12 RT-QuIC assay follows a modified version of
the protocols described in [27, 28]. K12CFh was thawed
from − 70 °C and filtered through 100 kDa filters (Pall)
to remove preformed aggregates. Concentration was ad-
justed to 6.5 μM ~ 0.1 mg/mL K12CFh in a buffer
containing 40mM HEPES, pH 7.4, 400 mM NaF, 40 μM
heparin, and 10 μM thioflavin T (ThT). These reaction
conditions were reached following the framework de-
scribed in [23]. The K12CFh solution was thoroughly
mixed in a polypropylene boat by gentle rocking for ~
10 s and 48 μL or 49 μL mix was added to each well of a
384-well optically clear bottom plate (NUNC) using a
multichannel pipettor. Brain homogenates (BHs) were
thawed from storage at 10% w/v in ice cold PBS and
serially diluted in 10-fold steps using a dilution buffer
containing 0.53% tau-free mouse (KO; B6.129S4(Cg)-
Mapttm1(EGFP)Klt/J from Jackson Laboratories) and 1x N-
2 Supplement (Gibco) + 10mM HEPES. Inclusion of
tau-free mouse BH and N-2 supplement were critical for
preventing spontaneous aggregation of the K12CFh tau
fragment. One or two μL of BH dilutions were seeded
into quadruplicate or octuplicate wells for a final reac-
tion volume of 50 μL in each well. Plates were sealed
with clear adhesive sealing tape and placed in an Omega
FLUOStar plate reader pre-warmed to 42 °C and sub-
jected to rounds of 1 min shaking, 500 rpm, orbital, and
1 min rest, with ThT fluorescence reads (450 excitation,
480 emission) taken every 15 min.
FTIR analysis of K12 RT-QuIC products
Once ThT fluorescence reached a plateau, and prior to
spontaneous fibril formation in mock-seeded control (tau
KO-seeded) wells, reactions were stopped and RT-QuIC
products were recovered by scraping the bottom of the
microplate wells with a pipette tip. Eight replicate reac-
tions seeded with a 10− 4 dilution of the designated BH
were pooled in 0.5mL microfuge tubes and centrifuged at
13,100 x g for 10min, at 4 °C. Supernatant containing sol-
uble K12CFh and other buffer components was discarded,
and pellets were washed twice with 400 μL H2O. Pellets
were resuspended in 5 μL H2O and subjected to attenu-
ated total reflectance (ATR) Fourier transform infrared
(FTIR) spectroscopy. 1.5 μL H2O-protein slurry was ap-
plied to a Perkin-Elmer Spectrum100 FTIR with an ATR
diamond attachment and dried with a gentle flow of dry
air. Prior to scanning, sample and electronics chambers
were purged with a constant flow of dry air. 100 replicate
scans were averaged from 4000 to 800 cm− 1, normalized
to amide I intensity (~ 1630 cm− 1 peak), and second deriv-
atives were taken with 9 points for slope analysis.
Electron microscopy of K12 RT-QuIC products
Prior to pelleting RT-QuIC products for FTIR, ~ 50 μL
of pooled reactions seeded with 10− 4 BH dilutions were
taken and wicked onto grids for transmission electron
microscopy (TEM). Ultrathin C film on lacey carbon
support film (400 mesh, Copper, TedPella Prod# 01824)
were glow discharged and incubated with fibril solutions
for 30 min at room temperature. Grids were washed 3
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times with Milli-Q (Millipore)-purified water prior to
being stained with Nano-W (Nanoprobes #2018–5) stain
for 15 min and wicked dry. Images were acquired on a
T12 (Thermo Fisher) transmission electron microscope
operating at 120 kV with a Rio (Gatan) CMOS camera.
LogSD50 and standard error statistical calculation
As a measure of seed concentrations in samples, we
employed logSD50 calculations using the Spearman-Kärber
method, which determine the log10 dilution at which 50% of
wells give ThT fluorescence greater than 100 times the
standard deviation of baseline fluorescence (threshold), prior
to 60 h [11]. LogSD50/mg tissue values represent a determin-
ation from a single serial dilution of a brain homogenate with
eight replicate reactions at dilutions from 10− 3 –10− 10, with
a final adjustment to report SD50 seeding units per mg brain
tissue. LogSD50 = xp = 1 + 1/2d - d∑p with xp = 1 being the
highest log dilution giving 8/8 positive responses; d = log
dilution factor; p = proportion positive at a given dose;
∑p = the sum of values of p for xp = 1 and all higher dilu-
tions [11]. Error bars represent the standard error calcu-
lated with the formula [∑(p(1-p))/n-1)]1/2 where n =
number of replicates. This method of error estimation
is further described in [11].
Analytical sensitivity estimation
To estimate the analytical sensitivity of K12 tau RT-QuIC,
synthetic K12CFh fibrils were assayed over serial dilutions
of a known concentration of starting fibrils. Fibrils were
generated by seeding 6.5 μM K12CFh substrate with either
AD, PiD, or KO BH at 10− 4 dilution in conditions identi-
cal to those described above for K12 RT-QuIC. Fibrils
were scraped from the microwell plate and analyzed by
SDS-PAGE for percent conversion of substrate to approxi-
mate the concentration of fibrils generated. We estimated
that nearly ~ 100% of the K12CFh was converted in all re-
action conditions. Serial dilutions of fibrils was conducted
identically to those for brain homogenate, in a background
of 10mM HEPES pH 7.4, 1x N-2, and 0.53% KO BH.
Results
K12CFh fibrillizes in the presence of 3R and 3R/4R tau seeds
Multiple reaction conditions including temperature, shak-
ing speed, substrate concentration, addition of salts, and
co-factors were tested before arriving at the present K12
RT-QuIC reaction conditions. Using a strategy we de-
scribed previously [23], we found that 400mM NaF pro-
vided the highest fold separation of lag phases (time to
threshold at which ThT fluorescence exceeded 100 stand-
ard deviations of the baseline fluorescence) between posi-
tive (AD- and PiD-seeded) and negative (KO-seeded)
reactions (Additional file 2). Using these reaction condi-
tions, we observed seeded fibrillization of the K12CFh sub-
strate, indicated by increased ThT fluorescence, in some
reactions seeded with brain homogenate dilutions as ex-
treme as 10− 9 and 10− 8 for AD and PiD, respectively,
Fig. 2 Primary ThT fluorescence data of K12 RT-QuIC endpoint dilution analyses. Panels show traces from 8 replicate reactions at the designated
dilutions of tau-free mouse brain (KO), cerebrovascular disease (CVD), progressive supranuclear palsy (PSP), Alzheimer disease (AD), and Pick
disease (PiD) brain homogenates. The fractions in the upper left corner of each panel indicate the ThT-positive/total replicate reactions
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within 50 h (Fig. 2). In contrast, brains that either lacked
immunohistochemically detectable tau pathology, e.g. a
cerebrovascular disease (CVD) case, or had 4R tau path-
ology (a PSP case), seeded fibrillization of K12CFh at only
10− 3 – 10− 5 dilution of brain homogenate. These initial ex-
periments indicated preference of the K12CFh substrate for
seeding by the tau aggregates of AD and PiD.
K12CFh detects PiD, AD, CTE seeds preferentially over 4R
tau seeds
To further explore the seeding selectivity of the K12CFh
substrate, we performed serial dilution analyses on several
brain homogenates with confirmed 3R pathology (PiD),
mixed 3R/4R pathology (sAD, fAD, CTE, PART), and
controls that had either 4R pathology (PSP, CBD, AGD)
or lacked tau pathology according to immunohistochemi-
cal analysis. Figure 3 summarizes these data in terms of
logSD50/mg tissue. An SD50 is a unit of seeding activity
that gives a positive reaction in 50% of replicate reactions.
Thus logSD50/mg tissue values represent the concentra-
tion of seeding units measured by the assay. PiD BHs had
a mean log SD50/mg tissue of 7.5 ± 0.6 (±standard devi-
ation), very similar to that obtained previously using the
3R RT-QuIC assay [27]. The AD and CTE brains with 3R/
4R tau pathology had similarly high tau seeding activities
of 8.3 ± 0.4 (n = 8) and 7.5–7.6 (n = 2), respectively. The
brains with 4R tau pathology reactions all had much lower
seeding activities (mean log SD50/mg tissue = 5.1 ± 0.7;
n = 13), albeit higher than those of brains that were immu-
nohistochemically negative for tau pathology (mean log
Fig. 3 Seed concentration (LogSD50/mg brain) determinations of 3R, 3R/4R, 4R, and immunohistochemically (IHC) tau-negative brain
homogenates by K12 RT-QuIC. Points represent logSD50/mg brain values calculated for a dilution series with a brain homogenate with 8 replicate
reactions at each dilution. Error bars represent the standard error of logSD50/mg brain determined by the equation described in Methods. Vertical
dotted lines represent mean logSD50/mg brain values across the designated brain homogenate types. PiD, Pick disease; sAD, sporadic AD; fAD,
familial AD; CTE, chronic traumatic encephalopathy; PART, primary age-related tauopathy; PSP, progressive supranuclear palsy; CBD, corticobasal
degeneration; AGD, argyrophilic grain disease; IVS10 + 3G > A FTDP, frontotemporal dementia with parkinsonism; MSA, multiple system atrophy;
PD, Parkinson’s disease; DLBD, diffuse Lewy body dementia; FTLD-TDP43, frontotemporal lobar degeneration with TDP43 protein; ALS,
amyotrophic lateral sclerosis; SC, senile change; CVD, cerebrovascular disease
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SD50/mg tissue = 4.5 ± 0.7; n = 17). Cut-off times for log
SD50/mg tissue determinations were set to 60 h based on
observations that no further PiD-, AD-, or CTE-seeded re-
actions exceeded 100 standard deviations of the baseline
ThT fluorescence at time points beyond 60 h. Spontan-
eous conversion of K12CFh was not observed in tau KO-
seeded wells prior to 120 h. Spearman-Kärber based esti-
mations of log SD50/mg tissue values for various tau ag-
gregation disease cases and controls are summarized in
Table 1 for comparison between K12, AD (3R/4R), 3R,
and 4R tau RT-QuIC assays.
Maximum ThT fluorescence distinguishes 3R- from 3R/4R-
seeded reactions
Our initial comparisons of AD- and PiD-seeded K12 RT-
QuIC reactions indicated several fold higher maximum
ThT fluorescence amplitudes in the AD-seeded reactions
(Fig. 2, bottom two rows). Remarkably, this amplitude
Fig. 4 ThT amplitudes between 3R and 3R/4R-seeded K12CFh reactions correlate with FTIR banding patterns. a. ThT maxima within 30 h of K12
RT-QuIC reactions seeded with individual patient BHs at 10− 4 dilution in octuplicate; points and bars represent mean ± SD. b. Second derivative
FTIR spectra of pooled reactions recovered from ThT maxima analysis reactions summarized in panel a. Each trace represents the 8 pooled
reactions, seeded with a 10− 4 BH dilution from an individual patient. Inset: tyrosine vibrational mode. c. Transmission electron micrographs of
representative 3R/4R (AD, CTE), 3R (PiD), and control (CVD) RT-QuIC products, recovered from plates at assay endpoint; bars represent 200 nm.
Asterisks denote TEM grid structures
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difference was seen over a large (10− 3–10− 6) range of BH
dilutions indicating that it was primarily the character, ra-
ther than the concentration, of the seeds in the AD versus
PiD brain specimens that determined the divergent fluor-
escence amplitudes. These fluorescence maxima differ-
ences were also seen in comparisons of reactions seeded
with 8 PiD brain homogenates (~ 21,000 relative fluores-
cence units) compared to 2 fAD, 6 sAD, 2 CTE, and 3
PART brain homogenates (~ 50,000 - 150,000) (Fig. 4a).
Modifying reaction conditions such as temperature, beads,
fluorescence gain setting, or concentrations of K12CFh,
ThT, NaF, and heparin all changed absolute maximum
ThT values, but relative amplitude differences between
PiD- and AD-seeded reactions remained (Additional file 3).
These results indicated that PiD and AD seeds induced
the formation of distinct K12 RT-QuIC products over a
range of conditions. However, at extreme (near end-point)
dilutions of PiD BH, the consistency of the relatively low
ThT maxima was diminished, as observed with a 10− 7 di-
lution in Fig. 2.
ThT fluorescence amplitudes correlate with distinct fibril
structures of 3R versus 3R/4R-seeded K12 RT-QuIC
reactions
To investigate if ThT fluorescence differences correlate to
structural properties of the brain homogenate-seeded
fibrils, we recovered RT-QuIC products from microwell
plates and analyzed them by ATR-FTIR spectroscopy.
Figure 4b shows second derivative FTIR spectra of 3R-
seeded (red traces) and 3R/4R-seeded (green, orange, blue
Fig. 5 Comparison of the sensitivity of the AD RT-QuIC (a) and K12 RT-QuIC (b) assays. Data points represent the time for an individual reaction
to exceed a ThT fluorescence threshold of 100 * SD of baseline fluorescence for the designated BH and dilution. Horizontally aligned overlapping
points at 30 h (AD RT-QuIC) and 120 h (K12 RT-QuIC) represent reactions for which ThT fluorescence did not exceed the threshold, indicating no
fibrils formed. Shaded area in a shows reaction times during which at least one replicate KO-seeded reaction exceeded the threshold. Bracket on
upper right indicates time period in which the lack of spontaneous (KO-seeded) false positive reactions well beyond the assay cut-off time (60 h)
enhances confidence in the true positives seeded by AD brain. Different lag time scales are used in panels a and b because of the different
seeded polymerization kinetics obtained with the two assays. The 60–120 h timeframe is shown in b to document the increased stability of the
K12 RT-QuIC with respect to spontaneous nucleation and polymerization in the absence of any tau seeds (i.e. in the presence of KO
brain homogenate)
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traces) K12 tau RT-QuIC products. All traces suggest high
β-sheet content in the reaction products with several
peaks in the β-sheet region (1633, 1630, 1625, 1618 cm− 1).
The spectra of the PiD-seeded reaction products had
prominent 1633, 1625 cm− 1 β-sheet vibrational modes,
which were distinct from 3R/4R-seeded reaction products
with prominent 1630 and 1618 cm− 1 vibrations; these re-
sults provide evidence that two distinct conformers of
K12CFh aggregates resulted from the differential seeding
(3R versus 3R/4R) of K12 RT-QuIC reactions. Further
spectral differences were observed in the 1655–1700 cm− 1
region containing turn and other parallel/antiparallel
β-sheet bands as well as at 1516–7 cm− 1 where tyrosine
absorbs (Fig. 4b inset). Even further differences were evi-
dent in the fingerprint region below 1400 cm− 1, which is
rich in side chain vibrations (Additional file 4).
We confirmed the fibrillar morphology of K12 RT-
QuIC reaction products with transmission electron mi-
croscopy which indicated abundant elongated fibrils in
the AD-, PiD-, and CTE-seeded, but not in control
(CVD)-seeded, K12CFh products (Fig. 4c).
Mixed AD/PiD pathology experiments
To investigate what might be observed when assaying
samples with mixed AD/PiD pathology, we took AD
and PiD brain homogenates with nominally comparable
logSD50/mg tissue values, thus representing similar
(within several fold) seeding doses of the tau aggregates
therein, and mixed them together in ratios ranging
from 10:0–0:10 AD:PiD before analyzing ThT fluores-
cence amplitudes in the K12 RT-QuIC. Additional file 5
summarizes the maximum ThT values observed over
decreasing AD:PiD ratio at a total BH dilution of 10− 4.
Reactions seeded only with AD BH (10:0 AD:PiD)
showed characteristically high ThT fluorescence values
that decrease with a decreasing ratio of AD:PiD. How-
ever, surprisingly, even with the addition of 1/10
equivalent of PiD BH, the ThT fluorescence maxima of
the reactions dropped to levels approaching those ob-
tained with PiD BH alone. These results suggested that
either (1) PiD tau seeds are more efficient at seeding
K12CFh fibrillization, or (2) that this PiD BH had a sev-
eral fold higher seed concentration than the AD BH,
which is possible because of ~ 0.5 log margin of error
that we have observed is typical of end-point dilution
RT-QuIC titrations.
K12 RT-QuIC is as sensitive as AD RT-QuIC
By performing K12 RT-QuIC analysis on serial dilutions
of synthetic K12CFh fibrils, we were able to crudely esti-
mate the concentration of fibrils that the K12 RT-QuIC
assay can detect. Additional file 6 shows lag time analysis
of serial dilutions of synthetic K12CFh fibrils generated by
seeding with tau KO mouse BH (left), AD BH (middle),
and PiD BH (right) at known fibril concentrations in K12
RT-QuIC. Individual points represent the time to thresh-
old ThT fluorescence (fluorescence > 100*SD baseline) for
8 replicate reactions at the indicated dilutions. By
Spearman-Kärber analysis, the analytical sensitivity of the
assay was roughly ~ 75 fM for synthetic AD-seeded
K12CFh fibrils, and ~ 7.5 fM for both synthetic PiD-
seeded K12CFh fibrils and spontaneously converted (tau
KO mouse-seeded) fibrils, comparable to the analytical
sensitivity of the previously published AD tau RT-QuIC
[21]. Finally, we compared the AD and K12 RT-QuIC as-
says by endpoint analysis of 7 AD BHs. Figure 5 shows the
lag time, defined above, for 7 AD BHs assayed in AD RT-
QuIC (5A) versus in K12 RT-QuIC (5B). Grey circles in
both panels represent KO BH-seeded reactions, which
serve as negative controls. The AD RT-QuIC showed oc-
casional (5/48) positive reactions occurring in KO-seeded
wells, prior to the published assay endpoint of 30 h (grey
shaded area). Nonetheless, similar mean seed concentra-
tions for AD brain samples were obtained with Spearman-
Kärber analyses of end-point dilution data the two assays,
i.e., 8.7 +/− 0.2 and 8.4 +/− 0.2 log SD50/mg with AD tau
RT-QuIC and K12 RT-QuIC, respectively.
Discussion
Given that tau deposition appears to underlie the pathogen-
esis of multiple neurodegenerative diseases, it is important
to have robust and practical assays for different types of tau
aggregates for use in diagnostics and research. Tau RT-
QuIC assays exploit the fundamental self-propagating activ-
ity of pathological forms of tau, offering detection methods
that are more sensitive than, and complementary to, con-
ventional methods such as immunohistochemistry, im-
munoblotting, and ELISA. Thus, tau RT-QuIC assays allow
measurements of multiple types of tau aggregates whether
they represent the predominant cause of neurodegeneration
or much less abundant co-pathology that is secondary to
another disease process. Our K12 RT-QuIC assay allows
the ultrasensitive detection and discrimination of both 3R
and 3R/4R types of pathological tau using a single tau sub-
strate (K12CFh). From a practical perspective, this assay
halves the number of assays and recombinant tau substrates
required to measure these types of tau seeds. More funda-
mentally, our findings also demonstrate the different tem-
plating activities of 3R versus 3R/4R tau-associated
aggregates. However, our observation that the discrimin-
atory ability of the assay based on maximum ThT fluores-
cence can break down with extreme near-end-point
dilutions of BH (Fig. 2) suggests that 3R vs 3R/4R discrim-
ination should be performed on specimens with seed con-
centrations that are at least 10-fold above the end-point
dilution of the assay. Based on our current observations,
K12 RT-QuIC could be applied to postmortem brain sam-
ples to aid in the characterization of decedents’ molecular
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pathologies for diagnostic and research purposes. Presum-
ably, it can be similarly applied in animal models in patho-
genesis or preclinical therapeutic studies to follow the
accumulation of 3R and 3R/4R tau aggregates. Applications
to antemortem diagnosis or therapeutic trials in humans
will depend largely upon the ability to detect tau seeds in
accessible tissue or fluid specimens such as CSF, but such
capability remains to be shown.
A key to success in developing RT-QuIC or other seed
amplification assays is maximizing the kinetic difference be-
tween seeded and unseeded (spontaneous) polymerization
of the substrate molecules. In our experience the K12CFh
substrate is readily seeded but is less prone to spontaneous
polymerization than the tau fragments that we have used in
our previous tau RT-QuIC assays [21, 23, 28, 29]. This fea-
ture can improve assay sensitivity and specificity, which
may be crucial for detecting aggregates in accessible diag-
nostic specimens with relatively low tau seed concentra-
tions. Recently we have shown for six different RT-QuIC
assays that modification of the main anionic component in
the reaction mixture can also help to delay spontaneous fi-
bril formation [23]. In the case of the AD tau RT-QuIC
assay, this strategy made it possible to conduct the assay
using only the τ306–378 fragment in the presence of
weakly-hydrated anions (NaBr, NaI, NaClO4). Thus, overall,
we have simplified the amplification of AD tau aggregates
by two methods: (1) by modifying the ionic species present
in the reaction mixture of the original AD tau RT-QuIC
[23] and (2) by extending the τ306–378 fragment N-
terminally to include R1, and C-terminally to residue 400 in
this work.
The ability of K12 RT-QuIC to distinguish PiD- from
3R/4R-seeded reactions based on the ThT fluorescence
maxima and FTIR spectra of the reaction products sug-
gests that at least some of the distinct conformational
features of PiD and 3R/4R tau filaments can be imposed
on, and propagated by, the K12CFh tau fragment. The
1618–1633 cm− 1 range of the major spectral differences
indicated that they likely reflect variations in β-sheets
formed by the polypeptide backbone because, although
side-chain vibrations can absorb in this range, they typ-
ically make up only about 10% of the spectral intensity
[22]. Nonetheless, the spectral differences in the more
sidechain-rich range below 1400 cm− 1 are also consist-
ent with conformational differences. The divergent ThT
maxima exhibited by the 3R- versus 3R/4R-seeded
K12CFh fibrils might be due to distinct alignments of
the ThT fluorophores on fibrils with different amyloid
cores and/or to the differential bundling of the fibrils.
Our inability to discriminate between the 3R/4R seed
subtypes (e.g. AD, CTE and PART) could be because the
filament core conformations of AD and CTE, at least,
are closely similar to one another [15, 16]. Moreover,
PART pathology may be on a continuum with the tau
pathology of AD, as both involve deposition of 3R/4R
tau isoforms in the entorhinal cortex and hippocampus
in neurofibrillary tangles (NFTs); however PART by def-
inition lacks amyloid-β pathology (NFT+/Aβ−) [10, 12].
PART is further defined as having NFT pathology at or
below Braak stage IV [12]. Thus, there may be only a
quantitative difference between PART and AD tau de-
posits. This would mean that the low level of seeding ac-
tivity of PART brains (mean logSD50/mg tissue = 4–6)
reflects lesser deposition of AD-like tau. Interestingly, 2
of 3 PART samples had seeding levels comparable to
that of 4R tau and IHC tau-negative brain homogenates.
This intermediate seeding activity was also observed
with the original AD tau RT-QuIC assay (logSD50/mg
tissue: KO < PiD and 4R tauopathies < AD, Table 1)
[21], but not in the 3R or 4R tau RT-QuIC assays (com-
pare control logSD50/mg tissue values in 3R, 4R tau RT-
QuIC columns with KO averages in Table 1) [27, 29].
This seeding activity could therefore be a result of
PART-related tau, which has been described elsewhere
as nearly universally present at some level in aged brains
[6]. NFTs can even be found in the second and third de-
cades of life [7]. Thus, as we have now observed in two
assays designed to amplify AD tau filaments (here and
[21]), an elevated baseline level of tau seeding activity in
control brain specimens may be readily detectable due
to similarities of AD and PART tau deposits and the fre-
quent presence of the latter in the brains of clinically-
normal individuals at quantities that may not be detect-
able by immunohistochemistry.
Pick bodies are rarely seen in AD brains. However, in
PiD brains, whereas 3R tau filaments predominate, tau
filaments that contain 4R tau isoforms have also been
observed [37]. The fact that K12 RT-QuIC detects both
PiD- and AD-associated tau seeds raises the issue of
how the assay might respond quantitatively to brain
samples with mixed tau pathologies. Initially, using K12
RT-QuIC, we estimated an average of 8.3 log SD50/mg
AD brain compared to 7.45 log SD50/mg PiD brain
(Fig. 3), which suggested a greater deposition of tau
seeds in AD brains. This conclusion is difficult to dis-
entangle, however, from the possibility of different
seeding efficiencies of structurally distinct tau aggre-
gates [14–16]. For example, our assays of AD- and PiD-
seeded synthetic fibrils of predetermined concentration
revealed an additional log of sensitivity in detecting the
PiD-seeded fibrils (7.5 fM vs 75 fM, Additional file 6).
This suggests that the templating of K12CFh onto PiD-
seeded fibrils is more efficient. One possible explan-
ation is that the more tightly bundled AD fibrils may
present fewer exposed seeding surfaces for K12CFh in-
corporation, relative to the loosely dispersed filaments
of Pick bodies [31]. Also differences in the bundling or
organization of AD- versus PiD-seeded K12CFh fibrils
Metrick et al. Acta Neuropathologica Communications            (2020) 8:22 Page 10 of 13
may impede fragmentation or lateral secondary nucleation
to generate new seeding surfaces during RT-QuIC reac-
tions. When we assayed ratios of AD:PiD BHs that each
had ~ 8 log SD50/mg (PiD 7, AD 2 in Fig. 3) we expected
to see a linear reduction in ThT amplitude as the AD:PiD
ratio decreased. Instead, we saw disproportionate drop in
ThT fluorescence maximum even a 9:1 AD:PiD ratio
(Additional file 5), suggesting a favorability of the K12CFh
tau construct to adopt the PiD fold. However, it also re-
mains possible, considering the inherent inaccuracy in end-
point dilution RT-QuIC assays of several fold, that the PiD
BH had a higher seed concentration than the AD BH.
Nonetheless, both the data in Additional file 5 and the add-
itional log of sensitivity of K12 RT-QuIC for the PiD-
seeded synthetic fibrils (Additional file 6) are consistent
with more efficient seeding of K12CFh by PiD tau seeds.
Further studies on brain tissue with varying amounts of AD
(3R/4R) and PiD (mainly 3R but sometimes 4R) co-
pathology will be needed to fully understand the signifi-
cance of these observations.
Conclusions
In summary, we have described a single ultrasensitive assay
that detects both 3R and 3R/4R tau aggregates and discrimi-
nates the seeds of AD and CTE from those of PiD. This
assay simplifies the measurement of these seeds by providing
a single test that can substitute for our two previously de-
scribed 3R (PiD) and 3R/4R (AD) tau RT-QuIC assays, and
requires the preparation of one tau substrate, herein called
K12CFh, instead of the 2 required for our previous assays.
Further, this single K12CFh tau fragment showed less fre-
quent spontaneous fibrillization compared to the substrates
used in the AD RT-QuIC assay, improving the confidence
with which a true positive can be declared. Importantly, the
analytical sensitivity of the assay is consistent with those of
the previously-published AD and PiD tau RT-QuIC assays.
Surprisingly, given the strong selectivity of our previous
3R tau RT-QuIC assay, our results also show that 3R/4R
tau aggregates can seed the fibrilization of a pure 3R tau
fragment that is C-terminally extended. So, from a more
fundamental perspective, our biophysical characterization
of the products of K12 RT-QuIC provided evidence that
at least some features of the original conformations of the
aggregates are propagated faithfully in these fibrillization
reactions, making the assay a promising tool for further
studying the misfolding process or inhibitors thereof.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40478-020-0887-z.
Additional file 1. Purification of K12CFh tau. Following overnight
autoinduction of K12CFh-expressing E. coli, tau is bound to a his column
and eluted over a stepwise gradient of 23–100% buffer B (46–200 mM
imidazole). Designated fractions are pooled and precipitated in acetone
overnight, washed, dissolved in 8 M GdnHCl in PBS, and desalted by PD-
10 size exclusion column. K12CFh fractions void of GdnHCl are pooled
and stored at − 80 °C for future use.
Additional file 2. Salt optimization of the K12 tau RT-QuIC assay. Panels
represent lag time (time to threshold of ThT > 100*SD baseline fluores-
cence) for reactions seeded with serial dilutions of PiD and AD brain tis-
sue in four salts at 400 mM. Top: addition of 40 μM heparin; bottom:
absence of heparin.
Additional file 3. Robustness of ThT amplitude differences with
modified reaction conditions. Panels represent mean ThT amplitude data
for three PiD and three AD brain homogenate reactions seeded at 1 ×
10− 4 dilution in K12 tau RT-QuIC. Each panel shows a variation of a reac-
tion condition (A, tau concentration; B, ThT concentration; C, NaF concen-
tration; D, addition of silica beads; E, heparin concentration; F, plate
reader gain, G; temperature of ThT read) beyond that of the optimized
conditions listed in the figure. For gain and temperature plots, the same
reaction at endpoint was scanned over increasing gain and temperature
of the plate holder.
Additional file 4. Second derivative FTIR spectra of PiD (3R)-, AD (3R/
4R)- and CTE (3R/4R)-seeded K12CFh products in fingerprint region from
800 to 1200 cm− 1. Each trace represents spectra from eight pooled K12
RT-QuIC reaction products seeded with an individual 1 × 10− 4 dilution of
brain homogenate. Multiple traces represent reaction products seeded
with brain homogenate from separate individuals: eight PiD (red), three
sAD (orange), three fAD (green), and three CTE (blue).
Additional file 5. K12 RT-QuIC performance in the presence of AD and
PiD tau seeds. Sixteen replicate K12 RT-QuIC reactions were performed at
the given ratio of AD:PiD seeds.
Additional file 6. Analytical sensitivity of K12 RT-QuIC seeded with syn-
thetic K12CFh fibrils. Panels represent lag time analysis (time where ThT
fluorescence exceeded 100*SD baseline fluorescence) for eight replicate
reactions seeded with the designated synthetic K12CFh fibril concentra-
tions. Assay conditions and dilution buffer were identical to those de-
scribed in methods.
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